Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Mansfield C, Thomas N, Gebben D, Lucas M, Hauber AB. Preferences for multiple sclerosis treatments: using a discrete-choice experiment to examine differences across subgroups of US patients. Int J MS Care. 2017 Jul;19(4):172-83. doi: 10.7224/1537-2073.2016-039
Henderson GE, Cadigan RJ, Edwards TP, Conlon I, Nelson AG, Evans JP, Davis AM, Zimmer C, Weiner BJ. Characterizing biobank organizations in the U.S.: results from a national survey. Genome Med. 2013 Jan 25;5(1):3. doi: 10.1186/gm407